Literature DB >> 10844707

Measuring cognitive change in a cohort of patients with Alzheimer's disease.

D R Galasko1, R L Gould, I S Abramson, D P Salmon.   

Abstract

Annualized rates of cognitive change in Alzheimer's disease (AD), an important index of disease progression, show marked variability. To determine factors leading to such variability, we computed rates of change in a cohort of patients with AD tested annually with the Mini Mental State Examination (MMSE) and the more detailed Dementia Rating Scale (DRS). Estimates of rates of change (slopes) and intercepts were calculated using least squares and best linear unbiased predictors (BLUPs). Potential predictors of rates of change were examined using multivariate linear regression analysis. We found that the MMSE had more noise than the DRS. For the MMSE, slopes showed a moderate floor effect and a slight ceiling, depending on initial MMSE scores. These effects were less prominent for the DRS, for which slopes increased as intercepts decreased. In analyses of predictors of change, the MMSE was less useful than the DRS. In multiple linear regression models using DRS data, predictors showed statistically stronger effects and explained a greater extent of variation of slopes than did similar models using MMSE data. For example, among patients who died and underwent brain examination at autopsy, neuropathology of Lewy bodies plus AD (Lewy Body variant; LBV) was associated with significantly faster rates of cognitive decline compared to pure AD in analyses that used the DRS, but only trends were identified with the MMSE. The metric properties and longitudinal characteristics of cognitive tests and the statistical methods used to calculate change are key factors in obtaining reliable estimates of change in studying cohorts of patients with AD. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 10844707     DOI: 10.1002/(sici)1097-0258(20000615/30)19:11/12<1421::aid-sim434>3.0.co;2-p

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  32 in total

1.  Effects of Comorbid Depression and Diabetes Mellitus on Cognitive Decline in Older Mexican Americans.

Authors:  Brian Downer; Benjamin N Vickers; Soham Al Snih; Mukaila Raji; Kyriakos S Markides
Journal:  J Am Geriatr Soc       Date:  2016-01       Impact factor: 5.562

2.  Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population-based studies.

Authors:  Cécile Proust-Lima; Hélène Amieva; Jean-François Dartigues; Hélène Jacqmin-Gadda
Journal:  Am J Epidemiol       Date:  2006-11-14       Impact factor: 4.897

3.  Evaluating the quality of longitudinal statistical applications in original publications on Alzheimer's disease.

Authors:  Chengjie Xiong; Yuxiao Tang; Gerald van Belle; J Philip Miller; Lenore J Launer; John C Morris
Journal:  Neuroepidemiology       Date:  2008-03-11       Impact factor: 3.282

4.  Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.

Authors:  Anders Gustavsson; Linus Jönsson; Johan Parmler; Niels Andreasen; Carina Wattmo; Åsa K Wallin; Lennart Minthon
Journal:  Eur J Health Econ       Date:  2011-08-06

5.  Relationship between metabolic and vascular conditions and cognitive decline among older Mexican Americans.

Authors:  Brian Downer; Mukaila A Raji; Kyriakos S Markides
Journal:  Int J Geriatr Psychiatry       Date:  2015-05-29       Impact factor: 3.485

6.  The association of age with rate of cognitive decline in elderly individuals residing in supporting care facilities.

Authors:  Ramit Ravona-Springer; Xiaodong Luo; James Schmeidler; Michael Wysocki; Gerson T Lesser; Michael A Rapp; Karen Dahlman; Hillel T Grossman; Vahram Haroutunian; Michal Schnaider Beeri
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Oct-Dec       Impact factor: 2.703

7.  The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease.

Authors:  Micaela Mitolo; David P Salmon; Simona Gardini; Douglas Galasko; Enzo Grossi; Paolo Caffarra
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

8.  Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies.

Authors:  Joanne M Hamilton; David P Salmon; Douglas Galasko; Rema Raman; Jenn Emond; Lawrence A Hansen; Eliezer Masliah; Leon J Thal
Journal:  Neuropsychology       Date:  2008-11       Impact factor: 3.295

9.  Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies.

Authors:  J A Schneider; Z Arvanitakis; L Yu; P A Boyle; S E Leurgans; D A Bennett
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

10.  Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen Aronson; Bart Van Baelen; Shane Kavanagh; Susanne Schwalen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.